| 1 | 25609193 | Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. | Lancet Diabetes Endocrinol | 2015 Mar |
2 |
| 2 | 25812383 | [Current status of clinical development of novel anti-diabetic drugs]. | Nihon Rinsho | 2015 Mar |
2 |
| 3 | 26115728 | Trelagliptin: First Global Approval. | Drugs | 2015 Jul |
1 |
| 4 | 26523434 | First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. | Expert Opin Pharmacother | 2015 |
2 |
| 5 | 26666159 | [Once-weekly DPP-4 inhibitor]. | Nihon Rinsho | 2015 Dec |
4 |
| 6 | 27181699 | Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study. | J Diabetes Investig | 2016 Sep |
1 |
| 7 | 27328054 | Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. | PLoS One | 2016 |
9 |
| 8 | 27809903 | Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. | Cardiovasc Diabetol | 2016 Nov 4 |
3 |
| 9 | 28829213 | Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. | Expert Opin Drug Saf | 2017 Nov |
3 |
| 10 | 28836351 | Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study. | J Diabetes Investig | 2018 Mar |
4 |
| 11 | 28883229 | Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes. | Intern Med | 2017 Oct 1 |
1 |
| 12 | 29066384 | Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms. | Eur J Pharm Sci | 2018 Jan 1 |
2 |
| 13 | 29076039 | Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol. | Diabetes Ther | 2017 Dec |
2 |
| 14 | 29093280 | Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study. | Endocr J | 2018 Feb 26 |
1 |
| 15 | 29787915 | Binding behavior of trelagliptin and human serum albumin: Molecular docking, dynamical simulation, and multi-spectroscopy. | Spectrochim Acta A Mol Biomol Spectrosc | 2018 Sep 5 |
2 |
| 16 | 29862617 | Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study. | Diabetes Obes Metab | 2018 Oct |
1 |
| 17 | 31214997 | Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor. | Diabetes Ther | 2019 Aug |
1 |
| 18 | 31822955 | Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan. | Eur J Clin Pharmacol | 2020 Feb |
1 |
| 19 | 32036216 | Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. | Biomed Pharmacother | 2020 May |
9 |
| 20 | 33049493 | The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1β-induced endothelial inflammation and monocytes attachment. | Int Immunopharmacol | 2020 Dec |
13 |
| 21 | 33421258 | The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. | J Biochem Mol Toxicol | 2021 Apr |
4 |
| 22 | 33728903 | Trelagliptin Mitigates Macrophage Infiltration by Preventing the Breakdown of the Blood-Brain Barrier in the Brain of Middle Cerebral Artery Occlusion Mice. | Chem Res Toxicol | 2021 Apr 19 |
4 |
| 23 | 33734011 | Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis. | Bioengineered | 2021 Dec |
16 |
| 24 | 33751359 | Trelagliptin Alleviates Lipopolysaccharide (LPS)-Induced Inflammation and Oxidative Stress in Acute Lung Injury Mice. | Inflammation | 2021 Aug |
3 |
| 25 | 34358551 | The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps. | Life Sci | 2021 Oct 15 |
8 |
| 26 | 34435315 | Trelagliptin ameliorates oxygen-glucose deprivation/reperfusion (OGD/R)-induced mitochondrial dysfunction and metabolic disturbance of endothelial cells. | Hum Cell | 2021 Nov |
7 |
| 27 | 34666245 | Trelagliptin ameliorates IL-1β-impaired chondrocyte function via the AMPK/SOX-9 pathway. | Mol Immunol | 2021 Dec |
22 |
| 28 | 35344848 | Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis. | Diabetes Metab Syndr | 2022 Apr |
1 |